S&P 500
(0.29%) 5 114.65 points
Dow Jones
(0.37%) 38 380 points
Nasdaq
(0.36%) 15 986 points
Oil
(-1.62%) $82.49
Gas
(5.25%) $2.02
Gold
(0.26%) $2 353.40
Silver
(0.25%) $27.61
Platinum
(3.96%) $958.65
USD/EUR
(-0.21%) $0.933
USD/NOK
(-0.34%) $10.99
USD/GBP
(-0.53%) $0.796
USD/RUB
(1.68%) $93.42

Realaus laiko atnaujinimai Hikma Pharmaceuticals PLC [HKMPY]

Birža: OTC Sektorius: Healthcare Pramonė: Drug Manufacturers—Specialty & Generic
Atnaujinta15 bal. 2024 @ 17:33

0.00% $ 46.50

Live Chart Being Loaded With Signals

Commentary (15 bal. 2024 @ 17:33):

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms...

Stats
Šios dienos apimtis 33.00
Vidutinė apimtis 130.00
Rinkos kapitalizacija 5.16B
Last Dividend $0.500 ( 2023-08-11 )
Next Dividend $0 ( N/A )
P/E 27.35
ATR14 $0 (0.00%)

Hikma Pharmaceuticals PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Hikma Pharmaceuticals PLC Finansinės ataskaitos

Annual 2023
Pajamos: $2.88B
Bruto pelnas: $1.39B (48.35 %)
EPS: $1.720
FY 2023
Pajamos: $2.88B
Bruto pelnas: $1.39B (48.35 %)
EPS: $1.720
FY 2022
Pajamos: $2.52B
Bruto pelnas: $1.24B (49.19 %)
EPS: $1.680
FY 2021
Pajamos: $2.55B
Bruto pelnas: $1.30B (50.96 %)
EPS: $3.57

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.380
(N/A)
$0
(N/A)
$0.740
(N/A)
$0
(N/A)
$0.500
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Hikma Pharmaceuticals PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.96 - Stable (0.75%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.150 2012-04-18
Last Dividend $0.500 2023-08-11
Next Dividend $0 N/A
Payout Date 2023-09-25
Next Payout Date N/A
# dividends 24 --
Total Paid Out $8.89 --
Avg. Dividend % Per Year 0.00% --
Score 3.65 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.96
Div. Directional Score 8.04 --
Next Divdend (Est)
(2024-06-21)
$0.505 Estimate 7.56 %
Dividend Stability
0.30 Poor
Dividend Score
3.65
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
WRTBY Ex Dividend Knight 2023-09-12 Semi-Annually 0 0.00%
MCHB Ex Dividend Knight 2023-08-09 Annually 0 0.00%
CNAF Ex Dividend Knight 2023-08-24 Quarterly 0 0.00%
SONVY Ex Dividend Knight 2023-06-14 Annually 0 0.00%
HEGIY Ex Dividend Knight 2023-09-15 Semi-Annually 0 0.00%
ANIOY Ex Dividend Knight 2023-07-13 Annually 0 0.00%
NODB Ex Dividend Junior 2023-10-17 Quarterly 0 0.00%
CUYTY Ex Dividend Junior 2023-09-29 Annually 0 0.00%
THUPY Ex Dividend Knight 2023-10-04 Semi-Annually 0 0.00%
IESFY Ex Dividend Knight 2023-05-16 Semi-Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06621.5008.6810.00[0 - 0.5]
returnOnAssetsTTM0.04051.2008.6510.00[0 - 0.3]
returnOnEquityTTM0.08641.500-0.151-0.227[0.1 - 1]
payoutRatioTTM0.723-1.0002.77-2.77[0 - 1]
currentRatioTTM1.5680.8007.165.73[1 - 3]
quickRatioTTM0.8900.8009.477.58[0.8 - 2.5]
cashRatioTTM0.1531.500-0.261-0.391[0.2 - 2]
debtRatioTTM0.254-1.5005.76-8.64[0 - 0.6]
interestCoverageTTM5.461.0009.099.09[3 - 30]
operatingCashFlowPerShareTTM4.792.008.4010.00[0 - 30]
freeCashFlowPerShareTTM2.962.008.5210.00[0 - 20]
debtEquityRatioTTM0.542-1.5007.83-10.00[0 - 2.5]
grossProfitMarginTTM0.4591.0005.695.69[0.2 - 0.8]
operatingProfitMarginTTM0.1651.0008.708.70[0.1 - 0.6]
cashFlowToDebtRatioTTM0.4441.0008.648.64[0.2 - 2]
assetTurnoverTTM0.6120.8009.257.40[0.5 - 2]
Total Score11.11

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM27.061.0007.370[1 - 100]
returnOnEquityTTM0.08642.50-0.0971-0.227[0.1 - 1.5]
freeCashFlowPerShareTTM2.962.009.0110.00[0 - 30]
dividendYielPercentageTTM3.051.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM4.792.008.4010.00[0 - 30]
payoutRatioTTM0.7231.5002.77-2.77[0 - 1]
pegRatioTTM1.9541.5000.3060[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1851.0007.880[0.1 - 0.5]
Total Score4.96

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.